Background: From February April 2020, the COVID-19 pandemic has swept through more than 200 countries and infected more than 100 million individuals globally, posing an unprecedented threat to human health. There are currently no specific antiviral treatments for COVID-19 and vaccination programs, whilst promising, remain in their infancy. A key to restricting the pandemic is the ability to minimize human-human transmission and predict the infection status of the population in the face of emerging SARS-CoV-2 variants. Success in this area is dependent on the rapid detection of COVID-19 positive individuals with current/previous SARS-CoV-2 infection status. The 3 categories of tests used to detect current or past viral infection are molecular, serologic, and antigen-detection assays.  Aims: This study aimed to evaluate the performance of the fluorescence LFIA Finecare TM 2019-nCoV S-RBD test along with its reader (Model No.: FS-113) in Iraqi setting. Giving a look on the prevalence of Covid19 infection in Baghdad city is our second aim. Study design A retrospective study on 75 randomly selected serum samples collected between 10 and 15 April 2020 was performed. They were checked for Covid-19 specific IgG and IgM responses by FinCare™ rapid semi-automated kit. Two aims were put in examinations.